BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 32923897)

  • 1. Immunological Differences Between Immune-Rich Estrogen Receptor-Positive and Immune-Rich Triple-Negative Breast Cancers.
    O'Meara T; Marczyk M; Qing T; Yaghoobi V; Blenman K; Cole K; Pelekanou V; Rimm DL; Pusztai L
    JCO Precis Oncol; 2020; 4():. PubMed ID: 32923897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer.
    Karn T; Jiang T; Hatzis C; Sänger N; El-Balat A; Rody A; Holtrich U; Becker S; Bianchini G; Pusztai L
    JAMA Oncol; 2017 Dec; 3(12):1707-1711. PubMed ID: 28750120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin-like growth factor 2 receptor is a key immune-related gene that is correlated with a poor prognosis in patients with triple-negative breast cancer: A bioinformatics analysis.
    Zhong Y; Ren X; Cao X; Xu Y; Song Y; Zhou Y; Mao F; Shen S; Wang Z; Sun Q
    Front Oncol; 2022; 12():871786. PubMed ID: 36330486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer.
    Yamashita N; Long M; Fushimi A; Yamamoto M; Hata T; Hagiwara M; Bhattacharya A; Hu Q; Wong KK; Liu S; Kufe D
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.
    Watanabe T; Hida AI; Inoue N; Imamura M; Fujimoto Y; Akazawa K; Hirota S; Miyoshi Y
    Breast Cancer Res Treat; 2018 Feb; 168(1):135-145. PubMed ID: 29168063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum-derived extracellular vesicles from breast cancer patients contribute to differential regulation of T-cell-mediated immune-escape mechanisms in breast cancer subtypes.
    Graham R; Gazinska P; Zhang B; Khiabany A; Sinha S; Alaguthurai T; Flores-Borja F; Vicencio J; Beuron F; Roxanis I; Matkowski R; Liam-Or R; Tutt A; Ng T; Al-Jamal KT; Zhou Y; Irshad S
    Front Immunol; 2023; 14():1204224. PubMed ID: 37441083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Standardized Evaluation Method for FOXP3+ Tregs and CD8+ T-cells in Breast Carcinoma: Association With Breast Carcinoma Subtypes, Stage and Prognosis.
    Papaioannou E; Sakellakis M; Melachrinou M; Tzoracoleftherakis E; Kalofonos H; Kourea E
    Anticancer Res; 2019 Mar; 39(3):1217-1232. PubMed ID: 30842152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS signaling enriched triple negative breast cancer is associated with favorable tumor immune microenvironment and better survival.
    Tokumaru Y; Oshi M; Katsuta E; Yan L; Satyananda V; Matsuhashi N; Futamura M; Akao Y; Yoshida K; Takabe K
    Am J Cancer Res; 2020; 10(3):897-907. PubMed ID: 32266098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen Receptor Positive Breast Cancer with High Expression of Androgen Receptor has Less Cytolytic Activity and Worse Response to Neoadjuvant Chemotherapy but Better Survival.
    Okano M; Oshi M; Butash AL; Asaoka M; Katsuta E; Peng X; Qi Q; Yan L; Takabe K
    Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
    Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterisation of the immune microenvironment of primary breast cancer and brain metastasis reveals depleted T-cell response associated to ARG2 expression.
    Giannoudis A; Varešlija D; Sharma V; Zakaria R; Platt-Higgins A; Rudland PS; Jenkinson MD; Young LS; Palmieri C
    ESMO Open; 2022 Dec; 7(6):100636. PubMed ID: 36423363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 and CD8 are associated with deficient mismatch repair status in triple-negative and HER2-positive breast cancers.
    Hou Y; Nitta H; Parwani AV; Li Z
    Hum Pathol; 2019 Apr; 86():108-114. PubMed ID: 30633926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High expression of polo-like kinase 1 is associated with TP53 inactivation, DNA repair deficiency, and worse prognosis in ER positive Her2 negative breast cancer.
    Takeshita T; Asaoka M; Katsuta E; Photiadis SJ; Narayanan S; Yan L; Takabe K
    Am J Transl Res; 2019; 11(10):6507-6521. PubMed ID: 31737202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple-Negative Breast Cancer with High Levels of Annexin A1 Expression Is Associated with Mast Cell Infiltration, Inflammation, and Angiogenesis.
    Okano M; Oshi M; Butash AL; Katsuta E; Tachibana K; Saito K; Okayama H; Peng X; Yan L; Kono K; Ohtake T; Takabe K
    Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31461932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TCGA RNA-Seq and Tumor-Infiltrating Lymphocyte Imaging Data Reveal Cold Tumor Signatures of Invasive Ductal Carcinomas and Estrogen Receptor-Positive Human Breast Tumors.
    Bou-Dargham MJ; Sha L; Sarker DB; Krakora-Compagno MZ; Chen Z; Zhang J; Sang QA
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
    de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M
    Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in ER (+) and/or PR (+) and HER2 (-) Breast Cancer.
    Du F; Zheng F; Han Y; Zhao J; Yuan P
    Front Pharmacol; 2022; 13():820437. PubMed ID: 35721151
    [No Abstract]   [Full Text] [Related]  

  • 18. Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer.
    Solinas C; Garaud S; De Silva P; Boisson A; Van den Eynden G; de Wind A; Risso P; Rodrigues Vitória J; Richard F; Migliori E; Noël G; Duvillier H; Craciun L; Veys I; Awada A; Detours V; Larsimont D; Piccart-Gebhart M; Willard-Gallo K
    Front Immunol; 2017; 8():1412. PubMed ID: 29163490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CIBERSORT analysis of TCGA and METABRIC identifies subgroups with better outcomes in triple negative breast cancer.
    Craven KE; Gökmen-Polar Y; Badve SS
    Sci Rep; 2021 Feb; 11(1):4691. PubMed ID: 33633150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
    Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
    Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.